Biome Grow Stock Revenue
| BIOIF Stock | USD 0.01 0 94.74% |
Biome Grow fundamentals help investors to digest information that contributes to Biome Grow's financial success or failures. It also enables traders to predict the movement of Biome Pink Sheet. The fundamental analysis module provides a way to measure Biome Grow's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biome Grow pink sheet.
Biome |
Biome Grow Company Revenue Analysis
Biome Grow's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Biome Grow reported 0.0 of revenue. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Biome Grow is currently under evaluation in revenue category among its peers. Market size based on revenue of Drug Manufacturers—Specialty & Generic industry is currently estimated at about 155,544. Biome Grow adds roughly 0.0 in revenue claiming only tiny portion of equities under Drug Manufacturers—Specialty & Generic industry.Biome Fundamentals
| Return On Equity | -4.37 | |||
| Return On Asset | -0.0844 | |||
| Current Valuation | 2.98 M | |||
| Shares Outstanding | 112.42 M | |||
| Shares Owned By Insiders | 47.31 % | |||
| Price To Earning | 0.48 X | |||
| Price To Book | 1.10 X | |||
| Price To Sales | 2.00 X | |||
| Gross Profit | 1.13 M | |||
| EBITDA | 313.61 K | |||
| Net Income | (139.93 K) | |||
| Cash And Equivalents | 2.1 M | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 3.51 M | |||
| Debt To Equity | 1.45 % | |||
| Current Ratio | 0.53 X | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (1.84 M) | |||
| Earnings Per Share | (0.15) X | |||
| Beta | 0.41 | |||
| Market Capitalization | 1.3 M | |||
| Total Asset | 11.07 M | |||
| Net Asset | 11.07 M |
About Biome Grow Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biome Grow's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biome Grow using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biome Grow based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Biome Pink Sheet
Biome Grow financial ratios help investors to determine whether Biome Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biome with respect to the benefits of owning Biome Grow security.